We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Hairy cell leukaemia with an IGH–BRAF fusion gene.
- Authors
Matsumoto, Kensuke; Kakazu, Naoki; Imataki, Osamu; Kondo, Akihiro; Kanaji, Nobuhiro; Kadowaki, Norimitsu
- Abstract
(D) BRAF inhibitor PLX-4720 paradoxically stimulates extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase kinase (MEK) phosphorylation in primary hairy cell leukaemia (HCL) cells. Similarly, Langabeer et al. reported that ERK phosphorylation remained unaltered upon PLX-4720 treatment in a patient with HCL that did not harbour the I BRAF i V600E mutation.[8] Hence, it may be advisable to not administer BRAF inhibitors to patients with HCL with an I IGH-BRAF i fusion gene. In conclusion, I BRAF i translocations should be assessed in patients with BRAF V600E-negative HCL, providing a more detailed diagnostic perspective. Reportedly, BRAF inhibitors are effective for HCL.[7] However, western blotting results indicated that the patient's HCL cells harbouring I IGH-BRAF i were resistant to the BRAF inhibitor PLX-4720.
- Subjects
GENE fusion; PROTEIN kinases; KINASES; PLASMACYTOMA; LEUKEMIA
- Publication
British Journal of Haematology, 2023, Vol 202, Issue 6, pe67
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.18980